The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 401–500 of 958
Targeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
The Gut–Brain Axis and Its Role in Controlling Eating Behavior in Intestinal Inflammation
Moran, G. W., & Thapaliya, G. (2021) · Nutrients · doi:10.3390/nu13030981 · Cited by 33
“Further, fluorescently labeled liraglutide penetrates the brain activating GLP-1 receptor-expressing neurons in the ARC to induce weight loss in rodents [54].”
BackgroundInvestigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
“(CART) which probably mediated the weight loss [40].”
BackgroundFessel, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133729 · Cited by 30
“…labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs, and in neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus [43], so that both liraglutide and semaglutide, may enter the brain by other means than via the BBB.”
BackgroundRuiz‐Pozo, V. A., Guevara‐Ramírez, P., Paz‐Cruz, E., Tamayo‐Trujillo, R., Cadena-Ullauri, S., Frías-Toral, E., Simancas‐Racines, D., Roshkova, Y. V. A., Reytor-González, C., & Zambrano, A. K. (2024) · Food and Agricultural Immunology · doi:10.1080/09540105.2024.2398042 · Cited by 30
“Additionally, it promotes insulin secretion and inhibits glucagon secretion (Holst, 2007; Kamakura et al., 2022; Secher et al., 2014).”
Igel, L. I., Saunders, K. H., & Fins, J. J. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0740-z · Cited by 25
Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
Welling, M. S., de Groot, C. J., Kleinendorst, L., van der Voorn, B., Burgerhart, J. S., van der Valk, E. S., van Haelst, M. M., van den Akker, E. L. T., & van Rossum, E. F. C. (2021) · Clinical Obesity · doi:10.1111/cob.12481 · Cited by 29
“This could be a possible mechanism through which liraglutide might induce satiety.(21,22) Interestingly, even though three of our cases have a deficient leptin-melanocortin pathway, they experienced weight loss and improved satiety during GLP-1 analogue treatment.”
BackgroundPharmacotherapy in Childhood Obesity
Kühnen, P., Biebermann, H., & Wiegand, S. (2021) · Hormone Research in Paediatrics · doi:10.1159/000518432 · Cited by 32
Zeng, N., Cutts, E. J., Lopez, C. B., Kaur, S., Duran, M., VIRKUS, S., & Hardaway, J. A. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.724030 · Cited by 27
Zhang, Z., Li, H., Su, Y., Ma, J., Yuan, Y., Yu, Z., Shi, M., Shao, S., Zhang, Z., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.814430 · Cited by 31
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“It has been shown that brainstem neurons in the nucleus tractus solitarius (NTS) can also modulate the activity of Agouti-related protein (AGRP) and proopiomelanocortin (POMC) neurons in the arcuate nucleus, key elements of the long term system and targets for GLP-1RAs ( 22 , 23 ).”
BackgroundBiology of obesity and weight regain: Implications for clinical practice
Rogge, M. M., & Gautam, B. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12504 · Cited by 29
“…action for the effect on food intake and appetite are not fully understood, it may involve stimulation of the POMC/cocaine-amphetamine regulator transcriptase (CART) neurons and indirect inhibition of neurons expressing NPY and agouti-related peptide AgRP in the hypothalamus (Secher et al., 2014).”
BackgroundCawthon, C. R., Blonde, G. D., Nisi, A. V., Bloomston, H. M., Krubitski, B., le Roux, C. W., & Spector, A. C. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad074 · Cited by 30
Neural Progenitor Cells and the Hypothalamus
Makrygianni, E. A., & Chrousos, G. P. (2023) · Cells · doi:10.3390/cells12141822 · Cited by 33
Madeo, S. F., Zagaroli, L., Vandelli, S., Calcaterra, V., Crinò, A., SANCTIS, L. D., Faienza, M. F., Fintini, D., Guazzarotti, L., Licenziati, M. R., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1382583 · Cited by 33
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
Hallmarks of Appetite: A Comprehensive Review of Hunger, Appetite, Satiation, and Satiety
Garutti, M., Sirico, M., Noto, C., Foffano, L., Hopkins, M., & Puglisi, F. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00604-w · Cited by 35
“GLP1 blood concentration rise shortly after the ingestion of nutri-ents and acting on several organs causes a reduction of intestinal motility, acid secretion from stomach, and appetite with a concomitant increase of insulin secretion [16] facilitating weight loss [17].”
Body-wide multi-omic counteraction of aging with GLP-1R agonism
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Chan, R. C. H., Chan, D. T.-M., Wang, Z., Zheng, X., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.014 · Cited by 38
Hölscher, C. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000087 · Cited by 25
Masaki, T., Ozeki, Y., Yoshida, Y., Okamoto, M., Miyamoto, S., Gotoh, K., & Shibata, H. (2022) · Metabolites · doi:10.3390/metabo12020147 · Cited by 30
“Both liraglutide and semaglutide have access to a limited number of brain regions, primarily circumventricular organs and a few sites in the hypothalamus [30].”
BackgroundMetabolic factors in the regulation of hypothalamic innate immune responses in obesity
Folick, A., Cheang, R. T., Valdearcos, M., & Koliwad, S. K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00666-z · Cited by 28
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 29
“…and cocaine-and amphetamine-regulated transcript (POMC/CART)-expressing neurons and indirect inhibition of neuropeptide Y (NPY) and agouti-related peptide (AgRP)-expressing neurons to increase measures of satiety and decrease hunger (Coveleskie et al., 2017; Secher et al., 2014).”
BackgroundSemaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23
“Craniopharyngiomas often extent to the medial hypothalamic nuclei, impacting important hormone regulatory sites such as the arcuate, ventromedial and dorsomedial nuclei, thereby affecting hormone production in the pituitary gland [7].”
BackgroundEffects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink‐Jensen, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70004 · Cited by 35
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 38
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“By contrast, chronic Ex-9 delivery to the ARC markedly attenuated liraglutide-induced weight loss (84) and chemogenetic stimulation of all GLP-1R–expressing neurons in the ARC reduced food intake in mice (59).”
InfluentialFitch, A., & Ingersoll, A. B. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1845534 · Cited by 26
“neurons and inhibition of orexigenic neurons [52], resulting in increased satiety and fullness, with reduced hunger and prospective food consumption [53].”
BackgroundCurrent and emerging medications for the management of obesity in adults
Walmsley, R., & Sumithran, P. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51871 · Cited by 25
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 26
“132 The access of the bigger GLP ‐ 1RA (albiglutide and dulaglutide) to the circumventricular organs is probably to some extent sterically hindered, which could explain their inferior effect on body weight.”
BackgroundHalf-Life Extending Modifications of Peptide YY3–36 Direct Receptor-Mediated Internalization
Bech, E. M., Kaiser, A., Bellmann‐Sickert, K., Bohr, S. S.-R., Sørensen, K. K., Elster, L., Hatzakis, N. S., Pedersen, S. L., Beck‐Sickinger, A. G., & Jensen, K. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00554 · Cited by 24
Borner, T., Shaulson, E. D., Tinsley, I. C., Stein, L. M., Horn, C. C., Hayes, M. R., Doyle, R. P., & Jonghe, B. C. D. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14089 · Cited by 25
“Ex4, increased polarity may be an important variable rather than the increased molecular size alone, given that GLP-1R agonists with greater molecular masses, such as liraglutide, have been shown to penetrate into the hindbrain and to stimulate direct GLP-1R activation.(30,42,43) It is also possible that the binding o…”
BackgroundLiraglutide improves lipid and carbohydrate metabolism of ovariectomized rats
Model, J. F. A., Lima, M. V., Ohlweiler, R., Vogt, É. L., Rocha, D. S., de Souza, S. K., Türck, P., Araújo, A. S. D. R., & Vinagre, A. S. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111158 · Cited by 24
Pratama, K. G., Nugroho, H., Hengky, A., Tandry, M., & Pauliana, P. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100533 · Cited by 22
Neuromedin U inhibits food intake partly by inhibiting gastric emptying
Dalbøge, L. S., Pedersen, S. L., Secher, T., Holst, B., Vrang, N., & Jelsing, J. (2015) · Peptides · doi:10.1016/j.peptides.2015.04.010 · Cited by 25
Self-citationThe central melanocortin system as a treatment target for obesity and diabetes: A brief overview
Goit, R. K., Taylor, A. W., & Lo, A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174956 · Cited by 24
Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo
Ast, J., Novak, A. N., Podewin, T., Fine, N. H. F., Jones, B. J., Tomás, A., Birke, R., Roßmann, K., Mathes, B., Eichhorst, J., et al. (2022) · JACS Au · doi:10.1021/jacsau.2c00130 · Cited by 25
Gaspar, R. S., Delafiori, J., Zuccoli, G. S., Carregari, V. C., do Prado, T. P., Morari, J., Sidarta-Oliveira, D., Solon, C., Catharino, R. R., ARAUJO, E. P. D., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00231.2022 · Cited by 22
Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake
Elliott, J. A., Reynolds, J. V., le Roux, C. W., & Docherty, N. G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1245140 · Cited by 23
“A proportion of POMC/CART neurons express the GLP-1 receptor, and administration of liraglutide, a synthetic GLP-1 analog, acts via POMC/CART neurons [183].”
BackgroundDi Loreto, C., Minarelli, V., Nasini, G., Norgiolini, R., & Del Sindaco, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01218-y · Cited by 21
“The weight effect is believed to be exerted via receptors in the central nervous system through a facilitated entry into additional regions of the nervous system due to the molecular structure of semaglutide [22].”
Current pharmacotherapies for obesity: A practical perspective
Golden, A. K. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12519 · Cited by 27
“Liraglutide 3.0 mg Liraglutide 3.0 mg is a GLP-1 receptor agonist that acts on the GLP-1 receptor in the hypothalamus to reduce hunger and increase satiety (FDA, 2015b; Secher et al., 2014).”
BackgroundInfluentialNg, V. W. W., Gerard, G., Koh, J. J. K., Loke, K. Y., Lee, Y. S., & Ng, N. B. H. (2024) · Clinical Obesity · doi:10.1111/cob.12642 · Cited by 21
“18,36,37 In addition, circulating GLP-1 acts on GLP-1 receptors in areas of the hindbrain beyond the hypothalamus that are involved in appetite homeostasis.”
BackgroundChrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 27
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.10.001 · Cited by 26
“Specifically, liraglutide binds to GLP-1 receptors on distinct neurons in the arcuate nucleus to directly stimulate pro-opiomelanocortin/cocaine- and amphetamine-regulated transcript (POMC/CART) neurons, and it indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide…”
BackgroundCurrent Perspectives on Long-term Obesity Pharmacotherapy
Wharton, S. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.07.005 · Cited by 30
Roth, E., Benoit, S., Quentin, B., Lam, B., Will, S., Ma, M. K. L., Heeley, N., Darwish, T., Shrestha, Y., Gribble, F. M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101118 · Cited by 21
“In particular, DVC POMC and TH neurons have been implicated in the response to peripheral CCK [22], whereas the anorectic response to GLP-1R agonists relies on the activation of ARH POMC neurons [23].”
BackgroundDischinger, U., Kötzner, L., Kovatcheva‐Datchary, P., Kleinschmidt, H., Haas, C., Perez, J., Presek, C., Koschker, A., Miras, A. D., Hankir, M. K., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155341 · Cited by 22
“It is well known that GLP-1 agonists mediate their effects via hypothalamic GLP-1 receptors [33,34,73].”
Iijima, T., Shibuya, M., Ito, Y., & Terauchi, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14000 · Cited by 21
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
Berman, C., Vidmar, A. P., & Chao, L. C. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.38 · Cited by 28
Oertel, M., Ziegler, C. G., Kohlhaas, M., Nickel, A. G., Kloock, S., Maack, C., Sequeira, V., Faßnacht, M., & Dischinger, U. (2024) · Endocrine Connections · doi:10.1530/ec-23-0398 · Cited by 25
“The effect that body weight is not maintained at the rodents' nadir but increases again over time, was observed before with PYY3-36 monotherapy (39, 40, 41), treatment with GLP-1 receptor agonists (33, 42), a combination of both (33) or even other obesity treatments (43).”
BackgroundKaisho, T., Nagai, H., Asakawa, T., Suzuki, N., Fujita, H., Matsumiya, K., Nishizawa, N., Kanematsu‐Yamaki, Y., Dote, K., Sakamoto, J.-I., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.176 · Cited by 21
GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve
Ueno, H., Ito, R., Abe, S., Ogino, H., Maruyama, M., Miyashita, H., Miyamoto, Y., Moritoh, Y., Tsujihata, Y., Takeuchi, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222653 · Cited by 25
“)-induced anorectic effect for 30 min in the overnight fasted-refed experiment [26, 36].”
BackgroundKatsuda, Y., Ohta, T., Shinohara, M., Tong, B., & Yamada, T. (2013) · Open Journal of Animal Sciences · doi:10.4236/ojas.2013.34050 · Cited by 27
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Mechanisms and pharmacotherapy of cancer cachexia‐associated anorexia
Sato, R., da Fonseca, G. W. P., das Neves, W., & von Haehling, S. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70031 · Cited by 25
“…70 showed in animal experi - ments that GLP-1 receptor antagonists suppressed the anorexic effect of oxytocin originating in the PVN. Secher et al. 71 demonstrated that the GLP-1 analog liraglutide-induced weight loss is mediated by direct stimulation of POMC/CART in the ARC and indirect…”
Siddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 25
“These pathways may indirectly influence cardiovascular health by improving systolic and diastolic function [23–25].”
Magdy, Y., Kamar, S. A., Habib, M. Z., Rady, H. Y., Rabei, M. R., & Khedr, S. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06834-7 · Cited by 25
“Notably, fluorescent probe experiments reveal that periph - erally administered liraglutide can cross the blood-brain barrier (BBB) and reach the brain either through passive diffusion or via binding to the central GLP-1R (Secher et al. 2014; Dong et al. 2022).”
Amyloid Beta Peptide Is an Endogenous Negative Allosteric Modulator of Leptin Receptor
Cecon, E., Lhomme, T., Maurice, T., Luka, M., Chen, M., Silva, A. J., Wauman, J., Zabeau, L., Tavernier, J. H., Prévot, V., et al. (2020) · Neuroendocrinology · doi:10.1159/000508105 · Cited by 20
“glucagon-like peptide 1 (Glp1), a hormone that, similarly to leptin, elicits an excitatory response in POMC neurons [59].”
BackgroundOsuga, Y., Harada, K., & Tsuboi, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.12.043 · Cited by 21
Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 25
Olszanecka‐Glinianowicz, M., Mazur, A., Chudek, J. T., Kos‐Kudła, B., Markuszewski, L., Dudek, D., Major, P., Małczak, P., Tarnowski, W., Jaworski, P., et al. (2023) · Nutrients · doi:10.3390/nu15071641 · Cited by 30
Craniopharyngioma—An update on metabolic and cognitive complications and new therapy
Erfurth, E. M. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13684 · Cited by 25
Adipose Tissue, Non-Communicable Diseases, and Physical Exercise: An Imperfect Triangle
Monsalve, F. A., González, D. R., Fernández-Tapia, B., & López, F. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417168 · Cited by 21
“The data show that liraglutide acts on POMC/CART (pro-opiomelanocortin/the cocaine-and amphetamine-regulated transcript) neurons, decreasing appetite and increasing levels of satiety in addition to generating a transient effect of slowing gastric emptying [114,115].”
BackgroundPharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
“32 Pharmacotherapy and Obesity The effects noted above demonstrate that GLP-1 receptor activation by native GLP-1 acts as a main regulator of food intake and can promote satiety with the combined effects of peripherally (intestinal component) and centrally (cerebral component) secreted GLP-1.”
Liang, J., Liu, H., Lv, G., Chen, X., Yang, Z., Hu, K., & Sun, H. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02416-2 · Cited by 30
Brønden, A., Naver, S. V., Knop, F. K., & Christensen, M. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1068288 · Cited by 22
“It is reasonable to assume that the chemical size and structure of albiglutide limits the access to GLP-1 receptors in the CNS, for example, in the circumventricular organs such as the area postrema [32] and parts of the hypothalamus such as the arcuate nucleus [33] (known as the infundibular nucleus in humans) and th…”
BackgroundApproaches to obesity management
Sweeting, A., & Caterson, I. D. (2017) · Internal Medicine Journal · doi:10.1111/imj.13474 · Cited by 25
Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4
Lee, S. J., Diener, K., Kaufman, S., Krieger, J.-P., Pettersen, K. G., Jejelava, N., Arnold, M., Watts, A. G., & Langhans, W. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.04.008 · Cited by 20
“Because the AP is the only area in the hindbrain accessible to peripherally injected liraglutide [17], it seems more likely that the activation of NTS and VLM neurons is indirectly mediated by GLP-1R activation in the AP.”
BackgroundIncretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 26
“Importantly, the fluorescent tag does not alter binding of the analogue to GLP-1R in vitro or its weight-lowering properties in diet-induced obese mice 189 .”
InfluentialBrar, A. S., Khanna, T., Sohal, A., Hatwal, J., Sharma, V., Singh, C. M., Batta, A., Chandra, P., & Mohan, B. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i1.111954 · Cited by 30
“In addition, ACE-I and ARB inhibit ROS generation and decrease cytokine levels that further oppose fibrosis, lipogenesis, and IR[274-278].”
The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
Melvin, A., le Roux, C. W., & Docherty, N. G. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0599-9 · Cited by 25
New Horizons: Is Obesity a Disorder of Neurotransmission?
Caron, A., & Michael, N. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab421 · Cited by 26
“nutrient signals including leptin (9-11), insulin (12,13), ghrelin (14,15), GLP-1 (11,16,17), glucose (18,19),”
Araújo, M. C., Soczek, S. H. S., Pontes, J. P., Marques, L. A. D. C., Santos, G. D. S., Simão, G., Bueno, L. R., Ferreira, D. M., Muscará, M. N., & Fernandes, E. S. (2022) · Cells · doi:10.3390/cells11081292 · Cited by 22
Park, S., Oh, S., & Kim, E. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102682 · Cited by 20
“Liraglutide mimicked caloric restriction in mice, resulting in dramatic anorexia and weight loss in our study and others (20, 21, 36).”
BackgroundInfluentialMultimodal 3D Mouse Brain Atlas Framework with the Skull-Derived Coordinate System
Perens, J., Salinas, C. G., Roostalu, U., Skytte, J. L., Gundlach, C., Hecksher‐Sørensen, J., Dahl, A. B., & Dyrby, T. B. (2023) · Neuroinformatics · doi:10.1007/s12021-023-09623-9 · Cited by 21
“, 2015), and distribution of fluorescently labelled molecules (Gabery et al., 2020; Secher et al., 2014).”
BackgroundSelf-citationBabateen, O., Korol, S. V., Jin, Z., Bhandage, A. K., Ahemaiti, A., & Birnir, B. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0191-0 · Cited by 23
Glucagon-like peptide-1 control of GnRH secretion in female sheep
Arbabi, L., Li, Q., Henry, B. A., & Clarke, I. J. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0335 · Cited by 19
Nutrient Combinations Sensed by L-Cell Receptors Potentiate GLP-1 Secretion
Sodum, N., Mattila, O., Sharma, R., Kamakura, R., Lehto, V., Walkowiak, J., Herzig, K., & Raza, G. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021087 · Cited by 21
“GLP-1 secretion signals the presence of food in the intestine and suppresses food intake centrally via the vagal nerve [17,18].”
BackgroundInteractions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism
Model, J. F. A., Normann, R. S., Vogt, É. L., Dentz, M. C. V., de Amaral, M., Xu, R., Bachvaroff, T. R., Spritzer, P. M., Chung, J. S., & Vinagre, A. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116623 · Cited by 22
Rodríguez, R., Hergarden, A. C., Krishnan, S., Morales, M., Lam, D., Tracy, T., Tang, T., Patton, A., Lee, C. R., Pant, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102156 · Cited by 34
GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
Li, H., Donelan, W., Wang, F., Zhang, P., Yang, L., Ding, Y., Tang, D., & Li, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.777026 · Cited by 21
Obesity and diabetes: the final frontier
Rendell, M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2168643 · Cited by 23
Greenwood, M. P., Greenwood, M., Bárez‐López, S., Hawkins, J. W., Short, K., Tatović, D., & Murphy, D. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101692 · Cited by 19
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
Cuttica, C. M., Briata, I. M., & DeCensi, A. (2023) · Nutrients · doi:10.3390/nu15173737 · Cited by 18
“GLP-1 inhibits food intake, mediating appetite suppression by directly stimulating POMC/CART neurons and indirectly inhibiting neurotransmission in neurons expressing neuropeptide Y and agouti-related peptide via GABA-dependent signaling [59].”
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Randolph, A. B., Zheng, H., & Rinaman, L. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.2063-23.2024 · Cited by 22
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[7,8] The effects of Liraglutide and Semaglutide on food intake are more pronounced than those of Dulaglutide and Albiglutide, supporting the perspective that the impact of GLP1RAs on appetite occurs centrally, while the effects on glycaemic control are peripherally mediated.”
Moo, E. V., Møller, T. C., Sørensen, F. A., Inoue, A., & Bräuner‐Osborne, H. (2025) · FEBS Journal · doi:10.1111/febs.17338 · Cited by 21
“The agonists have been shown to inhibit food intake, suppress appetite, delay gastric emptying, and reduce body weight [11 – 13].”
The Obesity–Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients
Sfera, A., Osorio, C. P., Inderias, L., Parker, V., Price, A. I., & Cummings, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00020 · Cited by 20
“These agents have been shown effective in halting weight gain in diabetic patients and their antiobesity action is most likely mediated via GLP-1 receptors expressed on POMC/ CART neurons (57) (Figure 1).”
BackgroundLong-acting glucagon-like peptide-1 receptor agonist—status December 2018
Holst, J. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.09 · Cited by 21
“com brain via the leaks of the blood brain barrier in the circumventricular organs, notably the area postrema, the median eminence and the subfornical organ (14).”
BackgroundDe Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“These areas are primarily found in the brain stem (area postrema, nucleus tractus solitarii, lateral parabrachial nucleus), as well as the hypothalamus (arcuate, paraventricular, ventromedial and dor-somedial nuclei) [29,30].”
BackgroundRecent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
An updated patent review of GLP-1 receptor agonists (2020-present)
Lu, W., Zhou, Z., Jiang, N., & Han, J. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2274905 · Cited by 17
“This occurs through the binding of GLP-1 receptors on neurons of the arcuate nucleus that express proopiomela-nocortin and cocaine-and amphetamine-regulated transcript (POMC/CART) [15].”
BackgroundProglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET
Deden, L. N., Booij, J., Grandjean, J., Homberg, J. R., Hazebroek, E. J., Gotthardt, M., & Boss, M. (2021) · Brain Sciences · doi:10.3390/brainsci11121647 · Cited by 21
“Moreover, to evaluate the mechanism by which liraglutide is able to reduce body weight, mice were injected subcutaneously with liraglutide labeled with a fluorescent probe [52].”
BackgroundKurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“While long-acting GLP-1RAs directly act on hypothalamic feeding centers [3,4], but don ’ t depend on vagal afferents or the hindbrain to inhibit food intake [3], GLP-1 is produced in a subset of neurons within the nucleus tractus solitarius (NTS) [7], and its infusion into the hepatic portal vein…”
InfluentialKhan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 21
de Wit, H. M., Vervoort, G., Jansen, H. J., de Galan, B. E., & Tack, C. J. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12447 · Cited by 21
Lehtonen, J., Schäffer, L., Rasch, M. G., Hecksher-Sørensen, J., & Ahnfelt-Rønne, J. (2015) · Islets · doi:10.1080/19382014.2015.1137415 · Cited by 17
Self-citation
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.